Lantheus Holdings (LNTH) Cash from Investing Activities (2014 - 2026)

Lantheus Holdings' (LNTH) quarterly Cash from Investing Activities came in at $26.0 million in Q1 2026, up 140.78% year-on-year from $10.8 million in Q1 2025, and up 325.77% on a QoQ basis from -$11.5 million in Q4 2025.

Lantheus Holdings (LNTH) Cash from Investing Activities (2014 - 2026) Analysis & Trends

Lantheus Holdings (LNTH) has 13 years of Cash from Investing Activities data on file, last reported at $26.0 million in Q1 2026.

  • On a quarterly basis, Cash from Investing Activities rose 140.78% year-over-year to $26.0 million in Q1 2026; TTM through Mar 2026 was -$537.5 million, a 193.37% decrease from a year earlier, with the FY2025 full-year figure at -$627.2 million, down 177.49% from the prior year.
  • Cash from Investing Activities for Q1 2026 stood at $26.0 million, up from -$11.5 million in the prior quarter.
  • Over the last five years, Cash from Investing Activities for LNTH reached as high as $83.2 million in Q3 2023 and fell as low as -$319.5 million in Q3 2025.
  • Historically, Cash from Investing Activities has averaged -$64.6 million across 5 years, with a median of -$20.7 million in 2023.
  • Across the five-year window, Cash from Investing Activities plunged 5725.79% in 2022 and surged 1466.47% in 2023, its largest moves.
  • Year by year, Cash from Investing Activities stood at -$264.7 million in 2022, then soared by 95.44% to -$12.1 million in 2023, then soared by 45.3% to -$6.6 million in 2024, then plunged by 74.34% to -$11.5 million in 2025, then jumped by 325.77% to $26.0 million in 2026.
  • Per Business Quant data, the three most recent Cash from Investing Activities figures were $26.0 million in Q1 2026, -$11.5 million in Q4 2025, and -$319.5 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Haleon 89.55 Bn 87.69 Bn - -
2 Teva Pharmaceutical Industries 36.00 Bn 32.26 Bn 1.97 Bn 229.00 Mn
3 Zoetis 32.59 Bn 30.65 Bn 1.62 Bn -87.00 Mn
4 Takeda Pharmaceutical 27.52 Bn 23.45 Bn 4.39 Bn -369.95 Mn
5 United Therapeutics 23.07 Bn 20.91 Bn 648.10 Mn 743.70 Mn
6 RedHill Biopharma 21.48 Bn 21.48 Bn - -
7 Viatris 20.28 Bn 18.47 Bn 1.16 Bn 277.40 Mn
8 Neurocrine Biosciences 17.78 Bn 16.47 Bn 800.70 Mn -506.20 Mn
9 Elanco Animal Health 12.62 Bn 12.19 Bn 785.00 Mn -60.00 Mn
10 Lantheus Holdings 6.98 Bn 6.48 Bn 230.92 Mn 25.99 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 25.99 Mn
Mar 31, 2026 25.99 Mn
Dec 31, 2025 -11.51 Mn
Dec 31, 2025 -11.51 Mn
Sep 30, 2025 -319.47 Mn
Sep 30, 2025 -319.47 Mn
Jun 30, 2025 -232.47 Mn
Jun 30, 2025 -232.47 Mn
Mar 31, 2025 -63.72 Mn
Mar 31, 2025 -63.72 Mn
Dec 31, 2024 -6.60 Mn
Dec 31, 2024 -6.60 Mn
Sep 30, 2024 -67.80 Mn
Sep 30, 2024 -67.80 Mn
Jun 30, 2024 -45.09 Mn
Jun 30, 2024 -45.09 Mn
Mar 31, 2024 -106.53 Mn
Mar 31, 2024 -106.53 Mn
Dec 31, 2023 -12.07 Mn
Dec 31, 2023 -12.07 Mn